Acticor Biotech
Latest round
- Series B
Last raised
- Nov 2019
Total raised
- $14M
Investors
- 4
About Acticor Biotech
Founded in 2013 and based in Paris, France, Acticor Biotech SAS, originated as a spin-off from the French National Institute of Health and Medical Research (INSERM), is a biopharmaceutical company that develops biologic drug candidates for the treatment of ischemic strokes.13 per share in Euronext Growth. Acticor Biotech addresses gaps in the treatment of thrombotic diseases, primarily acute ischemic stroke, with its drug candidate, glenzocimab. This therapy is a humanized monoclonal antibody fragment targeting the platelet glycoprotein GPVI, designed to enhance the safety and efficacy of thrombolysis during the acute phase of ischemic stroke. In 2022, glenzocimab received Priority Medicines (PRIME) status from the European Medicines Agency. The company has conducted several key clinical trials, including the ACTIMIS and ACTISAVE studies, both of which demonstrated positive results in terms of safety and efficacy. The current focus is on the GREEN study, evaluating glenzocimab in combination with mechanical thrombectomy.
Who invested in Acticor Biotech
4 investors across 2 rounds
See all investors in Acticor Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Acticor Biotech
Who invested in Acticor Biotech?
Acticor Biotech has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Acticor Biotech raised?
Acticor Biotech has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Acticor Biotech last raise money?
Acticor Biotech's most recent round on record is a Series B, in Nov 2019.
What does Acticor Biotech do?
Founded in 2013 and based in Paris, France, Acticor Biotech SAS, originated as a spin-off from the French National Institute of Health and Medical Research (INSERM), is a biopharmaceutical company that develops biologic drug candidates for the treatment of ischemic strokes.
Where is Acticor Biotech headquartered?
Acticor Biotech is headquartered in Paris, France.
Which VCs invest in companies like Acticor Biotech?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Acticor Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Acticor Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.